Drug Profile
Research programme: antibacterials - MerLion Pharmaceuticals
Alternative Names: Anti-virulence programme - MerLion; Hybrid programme - MerLion; Lipopeptide antibacterials - MerLionLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Combinature Biopharm
- Class Aminoglycosides; Lipoproteins; Macrolides; Oligosaccharides; Xanthenes
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Germany
- 18 Jan 2011 Preclinical development is ongoing in Germany
- 21 Aug 2006 Combinature Biopharm has been acquired by MerLion Pharmaceuticals